RELEASE PROFILE OF METFORMIN FROM F9 COMPARED WITH
FORMULATION AND DEVELOPMENT OF SUSTAINED RELEASE MATRIX TABLETS OF METFORMIN HYDROCHLORIDE
... different release mechanisms are operative, either of which is zero-order erosion and decreasing surface area, and dissolution of coated particles, but the overall tablet release profile comprising ...
11
FORMULATION AND IN-VITRO CHARACTERIZATION OF SUSTAINED RELEASE MATRIX TABLETS OF METFORMIN HYDROCHLORIDE
... target release profile, SR formulation of Metformin HCl tablets were developed with natural and synthetic polymers such as Xanthan gum, Guar gum, HPMC and Eudragit by wet granulation ...parameters. ...
8
Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes
... (XR) metformin has become available. Compared to conventional IR formulation, the XR offers some advantages; first of all the possibility to take the drug once a day and also a better gastrointestinal ...
8
Formulation Development of Metformin Hydrochloride Sustained Release Tablets
... 37 Metformin is an anti hyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma ...different from other classes of oral anti ...
137
FORMULATION AND EVALUATION OF EXTENDED RELEASE TABLETS OF METFORMIN HYDROCHLORIDE
... the release of drug by controlling the swelling and cross ...complications. Metformin hydrochloride is an orally administered biguanide, widely used in the management of type-2 diabetes, a common disease ...
6
GLUCOPHAGE XR (metformin hydrochloride) Extended-Release Tablets
... system. Metformin hydrochloride is combined with a drug release controlling polymer to form an "inner" phase, which is then incorporated as discrete particles into an "external" phase of a ...
35
Formulation and evaluation of metformin hydrochloride extended release tablets
... dissolution profile of formulation F5 was super imposable with the dissolution profile of the marketed product and concluded that F5 is better formulation and similar to innovator ...Controlled ...
7
Cost effectiveness analysis of metformin+dipeptidyl peptidase 4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
... Conclusions This study assessed the cost-effectiveness of most com- monly recommended in clinical guidelines T2D alterna- tive long-term treatment pathways. The treatment pathway with DPP-4i as the second-line therapy ...
12
DESIGN, FABRICATION AND EVALUATION OF DRUG RELEASE KINETICS FROM METFORMIN HYDROCHLORIDE SUSTAINED RELEASE MATRIX TABLETS BY USING NATURAL GUMS
... buffer) from 2 to 12 hours (900 ml), maintained at ...respectively compared with ...in-vitro release of Metformin hydrochloride sustained release ...the release studies were ...
8
Development and Charecterisation of Ramipril as Immediate Release and Metformin Hydrochloride as Sustained Release Bilayered Tablets
... suffering from such complications, it is apparent that anti diabetic and anti hypertensive drugs seem to be potential candidates for incorporating in a combination ...between Metformin HCl, Ramipril and ...
8
Formulation and Evaluation of Extended-Release Solid Dispersion of Metformin Hydrochloride
... The release data of selected SDs were examined according to the zero-order, first-order and Higuchi’s square root of time mathematical models, Hixson and Crowell powder dissolution method and Korsmeyer and Peppas ...
9
Formulation and In-Vitro Evaluation of Metformin Hydrochloride Sustained Release Tablets
... sustained release of metformin hydrochloride from ...drug release data were subjected to different models in order to evaluate release kinetics and mechanism of drug ...
6
FORMULATION AND IN-VITRO EVALUATION OF METFORMIN SUSTAINED RELEASE MATRIX TABLETS
... the release rate of active drugs 18, 20 ...drug release rate of metformin compared to individual ...polymers. Metformin hydrochloride obtained from natural sources as a drug for ...
8
The THE ROLE OF ASTAXANTHIN COMPARED WITH METFORMIN IN PREVENTING GLYCATED HUMAN SERUM ALBUMIN FROM POSSIBLE UNFOLDING: A MOLECULAR DYNAMIC STUDY
... to metformin has been successfully carried ...and release of bonds in gHSA. Unfolding on gHSA includes the release of bonds between sites A and ...of metformin-gHSA shows a significant ...
7
Formulation and Evaluation of Bilayer Tablets of Losartan Potassium for Immediate Release and Metformin Hydrochloride for Sustained Release
... and release properties, but the effect of different viscosity grades of HPMC K4M and HPMC K100M was not ...immediate release layer using Croscaramellose sodium as ...Sustained release layer of ...
141
Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer
... that, compared to metformin, MFB appears to more effectively impair S phase entry and/or progression through G2/M phase and decrease mammosphere formation, especially in the CD44 + CD24 -/low population ...
13
Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine
... Traditional non-opioid pharmacologic treatment to ameliorate symptoms of opioid withdrawal has mainly involved the off-label use of clonidine. This is be- cause there is a large release of norepinephrine during ...
10
<p>Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets</p>
... 11 Metformin is generally considered the fi rst choice oral medication for the treatment of type 2 diabetes, unless there is evidence of renal impairment or other ...12 Metformin does not undergo metabolism ...
10
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
... This clinical trial consisted of two independent studies, one a comparative pharmacokinetic study (Part 1), and the other a food effect study (Part 2). Each study had a random- ized, open-label, single dose, two-period, ...
8
Comparison of conventional and sustained-release formulation of metformin in type 2 diabetics
... with metformin appeared to decrease the risk of diabetes-related end-points including macro vascular complications in overweight diabetic patients and was associated with less weight gain and fewer hypoglycaemic ...
7